Implications for research
Continued collection of data on specific parameters of thrombosis and haemostasis from pregnant women affected by COVID-19 is necessary to further elucidate the incidence, prognostic value, and implications of coagulopathy, and thromboembolism in pregnancy.
More detailed investigation of coagulation abnormalities may also be useful. These could include studies such as specialised factor assays (taking into account the normal haemostatic changes that occur in pregnancy).
Determination of specific cut-off values of aberrant haemostatic parameters associated with adverse outcomes in pregnancy is needed. Given the rarity of the condition, even in the face of a global pandemic, and in absence of systematic studies or until data from randomised control trials become available, international registries can be of immense value in achieving this aim. The International Society on Thrombosis and Haemostasis has developed the Pregnancy and COVID-19-Associated Coagulopathy (COV-PREG-COAG) Registry, precisely to fulfil this aim. Participation in the Registry is open to health care providers worldwide and can be accessed at: https://redcap.isth.org/surveys/?s=4JPX9W98RH.